Science Explorer Back to mapMap

Most cited papers from Diabeteszentrum Bad Lauterberg

What are the most cited papers from Diabeteszentrum Bad Lauterberg?

The most cited paper from Diabeteszentrum Bad Lauterberg is "Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)" (S. E. Inzucchi, Richard M. Bergenstal, John B. Buse et al., 2012), with 3,934 citations. Next come "The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes" (3,921) and "Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach" (3,225).

Showing 50 of 61 papers. Every paper with more than 143 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) S. E. Inzucchi, Richard M. Bergenstal, John B. Buse et al. · Diabetologia Open access 19 Apr 2012 3,934
2 The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Daniel J. Drucker, Michael Albrecht Nauck · The Lancet Nov 2006 3,921
3 Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach Silvio E. Inzucchi, Richard M. Bergenstal, John B. Buse et al. · Diabetes Care Open access 19 Apr 2012 3,225
4 Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes Silvio E. Inzucchi, Richard M. Bergenstal, John B. Buse et al. · Diabetes Care Open access 13 Dec 2014 3,098
5 Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes Michael Albrecht Nauck, Anders H. Frid, Kjeld Hermansen et al. · Diabetes Care Open access 17 Oct 2008 1,128
6 Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients Michael Albrecht Nauck, N. Kleine, C. �rskov et al. · Diabetologia Open access Aug 1993 1,098
7 Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes Silvio E. Inzucchi, Richard M. Bergenstal, John B. Buse et al. · Diabetologia Open access 12 Jan 2015 699
8 Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial Michael Albrecht Nauck, Gary E. Meininger, D. Sheng et al. · Diabetes Obesity and Metabolism Open access 23 Jan 2007 669
9 Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects Carolyn Fiona Deacon, Michael Albrecht Nauck, Maibritt Toft-Nielsen et al. · Diabetes Sep 1995 667
10 Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial Richard E. Pratley, Michael Albrecht Nauck, Timothy Silleck Bailey et al. · The Lancet Apr 2010 590
11 Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study John B. Buse, Michael Albrecht Nauck, Thomas M. Forst et al. · The Lancet 6 Nov 2012 567
12 Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin Michael Albrecht Nauck, Stefano Del Prato, Juris Jendrik Meier et al. · Diabetes Care Open access 5 Aug 2011 535
13 Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. B. Willms, Jakob Werner, Jens Juul Holst et al. · The Journal of Clinical Endocrinology & Metabolism 1996 468
14 Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Michael Albrecht Nauck, Irfan Vardarli, Carolyn Fiona Deacon et al. · Diabetologia Open access 24 Sep 2010 464
15 A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study Michael Albrecht Nauck, S. Duran, D. Kim et al. · Diabetologia Open access 7 Dec 2006 441
16 Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans Michael Albrecht Nauck, Guido Kemmeries, Jens Juul Holst et al. · Diabetes Open access 23 Mar 2011 386
17 Normalization of Glucose Concentrations and Deceleration of Gastric Emptying after Solid Meals during Intravenous Glucagon-Like Peptide 1 in Patients with Type 2 Diabetes Juris Jendrik Meier, Baptist Gallwitz, Stefan Salmen et al. · The Journal of Clinical Endocrinology & Metabolism Jun 2003 374
18 Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance Kirsten Vollmer, Jens Juul Holst, Birgit Baller et al. · Diabetes Open access 6 Dec 2007 359
19 Update on developments with SGLT2 inhibitors in the management of type 2 diabetes Michael Albrecht Nauck · Drug Design Development and Therapy Open access Sep 2014 345
20 Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects Juris Jendrik Meier, Michael Albrecht Nauck, Daniel Kranz et al. · Diabetes Mar 2004 336
21 Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide I(7–36) amide in type I diabetic patients W. Creutzfeldt, N. Kleine, B. Willms et al. · Diabetes Care Jun 1996 336
22 Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study Richard E. Pratley, Michael Albrecht Nauck, Anthony H Barnett et al. · The Lancet Diabetes & Endocrinology 5 Feb 2014 327
23 Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia Juris Jendrik Meier, Baptist Gallwitz, Nina Siepmann et al. · Diabetologia Open access Jun 2003 317
24 Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue JOHAN H. JENDLE, Michael Albrecht Nauck, David Richard Matthews et al. · Diabetes Obesity and Metabolism Open access 22 Sep 2009 308
25 Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes Frauke Fehse, MICHAEL E. TRAUTMANN, Jens Juul Holst et al. · The Journal of Clinical Endocrinology & Metabolism Nov 2005 302
26 Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications Michael Albrecht Nauck · The American Journal of Medicine 30 Dec 2010 293
27 Glucagon-like peptide 1(GLP-1) in biology and pathology Juris Jendrik Meier, Michael Albrecht Nauck · Diabetes/Metabolism Research and Reviews Mar 2005 288
28 Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM Michael Albrecht Nauck, Daniel Wollschläger, Jakob Werner et al. · Diabetologia Open access 21 Nov 1996 288
29 Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Silvio E. Inzucchi, Richard M. Bergenstal, John B. Buse et al. · Diabetes Spectrum Open access Aug 2012 287
30 Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5) Michael Albrecht Nauck, Ruth S. Weinstock, Guillermo E. Umpierrez et al. · Diabetes Care Open access 18 Apr 2014 285
31 Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans Juris Jendrik Meier, Arnica Gethmann, Oliver Götze et al. · Diabetologia Open access 30 Jan 2006 275
32 Glucagon-Like Peptide 2 Stimulates Glucagon Secretion, Enhances Lipid Absorption, and Inhibits Gastric Acid Secretion in Humans Juris Jendrik Meier, Michael Albrecht Nauck, Andrea Pott et al. · Gastroenterology Open access 2006 264
33 Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes Helle Linnebjerg, Soomin Park, Prajakti A. Kothare et al. · Regulatory Peptides 17 Jul 2008 260
34 One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial Richard E. Pratley, Michael Albrecht Nauck, Timothy Silleck Bailey et al. · International Journal of Clinical Practice Open access Mar 2011 253
35 Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial Steven P. Marso, Neil R Poulter, Steven E. Nissen et al. · American Heart Journal Open access 2 Oct 2013 251
36 Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data Stefano Del Prato, Michael Albrecht Nauck, Santiago Durán-Garcia et al. · Diabetes Obesity and Metabolism 4 Mar 2015 234
37 Reduced Insulinotropic Effect of Gastric Inhibitory Polypeptide in First-Degree Relatives of Patients With Type 2 Diabetes Juris Jendrik Meier, Katrin Hücking, Jens Juul Holst et al. · Diabetes Nov 2001 231
38 A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes Michael Albrecht Nauck, John R. Petrie, Giorgio Sesti et al. · Diabetes Care Open access 10 Sep 2015 231
39 Gastric Inhibitory Polypeptide: the neglected incretin revisited Juris Jendrik Meier, Michael Albrecht Nauck, Wolfgang Ekkehard Schmidt et al. · Regulatory Peptides Jul 2002 226
40 Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes Michaëla Diamant, Michael Albrecht Nauck, Rimma M. Shaginian et al. · Diabetes Care 11 Jul 2014 226
41 Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee Hans Müller-Faßbender, Gerhard L. Bach, Wolfgang Haase et al. · Osteoarthritis and Cartilage Mar 1994 216
42 Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function? Juris Jendrik Meier, Michael Albrecht Nauck · Diabetes Open access 28 Apr 2010 214
43 Gastric inhibitory polypeptide (GIP) and insulin in obesity: Increased response to stimulation and defective feedback control of serum levels W. Creutzfeldt, Reinhold Ebert, B. Willms et al. · Diabetologia Open access 1978 214
44 Effects of Intravenous Glucagon-Like Peptide-1 on Gastric Emptying and Intragastric Distribution in Healthy Subjects: Relationships with Postprandial Glycemic and Insulinemic Responses Tanya J. Little, Amelia N. Pilichiewicz, Antonietta Russo et al. · The Journal of Clinical Endocrinology & Metabolism 21 Feb 2006 212
45 Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in the Pathogenesis of Type 2 Diabetes Michael Albrecht Nauck, Birgit Baller, Juris Jendrik Meier · Diabetes Dec 2004 209
46 Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study Thomas L. Seck, Michael Albrecht Nauck, D. Sheng et al. · International Journal of Clinical Practice Open access 4 Mar 2010 209
47 A Critical Analysis of the Clinical Use of Incretin-Based Therapies Michael Albrecht Nauck · Diabetes Care Open access 4 May 2013 205
48 Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study Michael Albrecht Nauck, Graham C. Ellis, Penny R. Fleck et al. · International Journal of Clinical Practice Open access 15 Dec 2008 205
49 GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes Nikolaos Mentis, Irfan Vardarli, L. Köthe et al. · Diabetes Open access 17 Feb 2011 197
50 Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia Mahesh Michael Umapathysivam, Michael Y. Lee, Karen L. Jones et al. · Diabetes Open access 2 Oct 2013 193

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.